Glaxosmithkline Pharmaceuticals Ltd Half Yearly Results

Gross Sales

1,785.11

1,923.79

1,825.42

1,735.06

1,718.65

Excise Duty

0

0

0

0

0

Net Sales

1,785.11

1,923.79

1,825.42

1,735.06

1,718.65

Other Operating Income

0

0

0

0

0

Other Income

79.93

75.75

74.87

40.64

81.95

Total Income

1,865.04

1,999.54

1,900.29

1,775.7

1,800.6

Total Expenditure

1,198.18

1,298.68

1,273.17

1,403.35

1,285.28

PBIDT

666.86

700.86

627.12

372.35

515.32

Interest

0.93

0.67

0.64

1.09

0.71

PBDT

665.93

700.19

626.48

371.26

514.61

Depreciation

32.95

33.52

33.27

35.21

34.47

Minority Interest Before NP

0

0

0

0

0

Tax

170.02

163.64

162.32

93.08

144.51

Deferred Tax

0.46

10.28

-3.94

2.77

-14.13

Reported Profit After Tax

462.5

492.75

434.83

240.2

349.76

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

462.5

492.75

434.83

240.2

349.76

Extra-ordinary Items

1.93

0

3.41

-160.91

12.09

Adjusted Profit After Extra-ordinary item

460.57

492.75

431.42

401.11

337.67

EPS (Unit Curr.)

27.17

29.09

25.43

14.18

19.88

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

120

0

320

Equity

169.41

169.41

169.41

169.41

169.41

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

37.35

36.43

34.35

21.46

29.98

PBDTM(%)

-

-

-

-

-

PATM(%)

25.9

25.61

23.82

13.84

20.35